专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4513005A SRS-A antagonists 失效
标题翻译： SRS-A拮抗剂
公开(公告)号：US4513005A
公开(公告)日：1985-04-23
申请号：US386570
申请日：1982-06-09
申请人： Stephen R. Baker , William B. Jamieson , William J. Ross , Alec Todd
发明人： Stephen R. Baker , William B. Jamieson , William J. Ross , Alec Todd
IPC分类号： C07B45/04 , C07C317/46 , C07C323/22 , C07C323/56 , C07C323/58 , C07D303/40 , C07D303/42 , C07D307/38 , C07D309/12 , C07D309/30 , C07D313/04 , C07F9/53 , C07K5/06 , C07C149/20 , A61K31/23 , A61K31/335
CPC分类号： C07D307/38 , C07B45/04 , C07C317/46 , C07C323/22 , C07C323/56 , C07C323/58 , C07D303/40 , C07D303/42 , C07D309/12 , C07D309/30 , C07D313/04 , C07F9/5304 , C07F9/5325 , C07K5/06034
摘要： There are described pharmacologically active compounds, useful in the treatment of allergic/inflammatory disorders involving SRS-A as causal mediator and which, in free acid form, are of formula I, ##STR1## in which R.sub.1 is (i) an aliphatic, saturated or unsaturated hydrocarbyl radical of up to 20 carbon atoms, unsubstituted or substituted by at least one substituent selected from halogen, hydroxy, C.sub.3-6 alkoxy, C.sub.3-6 cycloalkyl, aryl or heteroaryl, the cycloalkyl, aryl or heteroaryl being unsubstituted or substituted by at least one substituent selected from hydroxy, halogen and alkyl, alkenyl or alkynyl of up to 10 carbon atoms,(ii) cycloalkyl of 3 to 8 carbon atoms unsubstituted or substituted by alkyl, alkenyl or alkynyl of up to 16 carbon atoms, or(iii) aryl or heteroaryl, unsubstituted or substituted by hydroxyl, C.sub.1-4 alkoxy, halogen or alkyl, alkenyl or alkynyl of up to 16 carbon atoms; and R.sub.2 is(i) alkyl, cycloalkyl or alkenyl of up to 10 carbon atoms, unsubstituted or substituted by one or more substituents selected from aryl, cycloalkyl, halogen, hydroxy, NHR.sub.3 and COX, where R.sub.3 is H, C.sub.1-4 alkyl, aryl or an amino acid residue or COX, and X is OH, C.sub.1-4 alkyl, NH.sub.2 or an amino acid residue, or(ii) aryl or heteroaryl, unsubstituted or substituted by one or more substituents selected from C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.2-5 acyl, halogen, hydroxy, carboxy, nitro, trihalomethyl, phenyl, C.sub.1-4 acylamino and NHR.sub.4, where R.sub.4 is hydrogen or C.sub.1-4 alkyl; and Y is --S--, --SO-- or --SO.sub.2 --,with the proviso that when --YR.sub.2 is glutathionyl, cysteinyl or cysteinylglycinyl, then R.sub.1 is other than an unsubstituted alkatetraenyl or alkapentaenyl radical of 12 to 16 carbon atoms.
摘要翻译：描述了用于治疗涉及SRS-A作为因果介质的过敏性/炎症性疾病，其游离酸形式为式I的化学活性化合物，其中R 1是（i）脂族，至少20个碳原子的饱和或不饱和烃基，未被取代或被至少一个选自卤素，羟基，C 3-6烷氧基，C 3-6环烷基，芳基或杂芳基的取代基取代，环烷基，芳基或杂芳基是未取代或取代的至少一个选自羟基，卤素和至多10个碳原子的烷基，烯基或炔基的取代基，（ii）未被取代或被至多16个碳原子的烷基，烯基或炔基取代的3至8个碳原子的环烷基，或（iii）未被取代或被羟基，C 1-4烷氧基，卤素或至多16个碳原子的烷基，链烯基或炔基取代的芳基或杂芳基; 并且R 2是（i）至少10个碳原子的烷基，环烷基或链烯基，未被取代或被一个或多个选自芳基，环烷基，卤素，羟基，NHR 3和COX的取代基取代，其中R 3是H，C 1-4烷基，芳基或氨基酸残基或COX，X为OH，C 1-4烷基，NH 2或氨基酸残基，或（ii）未被取代或被一个或多个选自C 1-4烷基，C 1 -4-烷氧基，C 2-5酰基，卤素，羟基，羧基，硝基，三卤甲基，苯基，C 1-4酰基氨基和NHR 4，其中R 4是氢或C 1-4烷基; 并且Y是-S-，-SO-或-SO 2 - ，条件是当-YR 2是谷胱甘肽基，半胱氨酰基或半胱氨酰甘氨酰基时，则R 1不同于未被取代的具有12至16个碳原子的烷基四烯基或烷基五烯基。

2. 再颁专利

USRE33300E Oxiranes 失效
标题翻译：环氧乙烷
公开(公告)号：USRE33300E
公开(公告)日：1990-08-14
申请号：US430697
申请日：1989-11-01
申请人： Stephen R. Baker , William B. Jamieson , Alec Todd
发明人： Stephen R. Baker , William B. Jamieson , Alec Todd
IPC分类号： A61K31/165 , A61K31/10 , A61K31/135 , A61K31/16 , A61K31/19 , A61K31/195 , A61K31/215 , A61K31/22 , A61K31/235 , A61K31/275 , A61K31/41 , A61K38/00 , A61P11/00 , A61P37/08 , A61P43/00 , C07C17/26 , C07C17/354 , C07C33/20 , C07C33/30 , C07C67/00 , C07C313/00 , C07C315/02 , C07C317/00 , C07C317/14 , C07C317/18 , C07C317/28 , C07C317/44 , C07C317/46 , C07C317/48 , C07C319/14 , C07C323/12 , C07C323/16 , C07C323/25 , C07C323/52 , C07C323/56 , C07C323/58 , C07C323/60 , C07C323/65 , C07D257/04 , C07D257/06 , C07D303/02 , C07D303/04 , C07D303/08 , C07D303/12 , C07D303/14 , C07D303/32 , C07D303/38 , C07D303/40 , C07D303/46 , C07D307/88 , C07D309/12 , C07D405/10 , C07K5/06 , C07K5/062
CPC分类号： C07D257/04 , C07C17/2635 , C07C17/354 , C07C255/00 , C07C309/00 , C07C317/00 , C07C323/00 , C07C33/20 , C07C33/30 , C07D303/04 , C07D303/14 , C07D303/32 , C07D303/38 , C07D303/40 , C07D307/88 , C07D309/12 , C07D405/10 , C07K5/0606 , A61K38/00 , Y02P20/55
摘要： There are described compounds of formula ##STR1## in which n is 0, 1 or 2, R.sup.1 is a hydrocarbyl group optionally substituted with an optionally substituted phenyl group and containing from 5 to 30 carbon atoms, R.sup.2 is optionally substituted phenyl or C.sub.1-10 alkyl optionally substituted by one or more substituents selected from optionally protected hydroxyl, optionally protected carboxyl, nitrile, optionally protected tetrazolyl, --COR.sup.6 where R.sup.6 is C.sub.1-4 alkyl, C.sub.1-4 alkoxy, an optionally protected amino acid residue or --NR.sub.2.sup.7 where each R.sup.7 is hydrogen or C.sub.1-4 alkyl, and --NHR.sup.8 where R.sup.8 is hydrogen, a protecting group, an optionally protected amino acid residue, C.sub.1-4 alkyl or --COR.sup.9 where R.sup.9 is C.sub.1-4 alkyl or C.sub.1-4 alkoxy, and R.sup.3, R.sup.4 and R.sup.5 are each selected from hydrogen, carboxyl, C.sub.2-5 alkoxycarbonyl, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxyl, optionally protected tetrazolyl, halo, trifluoromethyl, nitrile, nitro and --CONR.sub.2.sup.10 where each R.sup.10 is hydrogen or C.sub.1-4 alkyl; and salts thereof. The compounds are leukotriene antagonists.

3. 发明授权

US4665189A Oxiranes 失效
标题翻译：环氧乙烷
公开(公告)号：US4665189A
公开(公告)日：1987-05-12
申请号：US635863
申请日：1984-07-30
申请人： Stephen R. Baker , William B. Jamieson , Alec Todd
发明人： Stephen R. Baker , William B. Jamieson , Alec Todd
IPC分类号： A61K31/165 , A61K31/10 , A61K31/135 , A61K31/16 , A61K31/19 , A61K31/195 , A61K31/215 , A61K31/22 , A61K31/235 , A61K31/275 , A61K31/41 , A61K38/00 , A61P11/00 , A61P37/08 , A61P43/00 , C07C17/26 , C07C17/354 , C07C33/20 , C07C33/30 , C07C67/00 , C07C313/00 , C07C315/02 , C07C317/00 , C07C317/14 , C07C317/18 , C07C317/28 , C07C317/44 , C07C317/46 , C07C317/48 , C07C319/14 , C07C323/12 , C07C323/16 , C07C323/25 , C07C323/52 , C07C323/56 , C07C323/58 , C07C323/60 , C07C323/65 , C07D257/04 , C07D257/06 , C07D303/02 , C07D303/04 , C07D303/08 , C07D303/12 , C07D303/14 , C07D303/32 , C07D303/38 , C07D303/40 , C07D303/46 , C07D307/88 , C07D309/12 , C07D405/10 , C07K5/06 , C07K5/062
CPC分类号： C07D257/04 , C07C17/2635 , C07C17/354 , C07C255/00 , C07C309/00 , C07C317/00 , C07C323/00 , C07C33/20 , C07C33/30 , C07D303/04 , C07D303/14 , C07D303/32 , C07D303/38 , C07D303/40 , C07D307/88 , C07D309/12 , C07D405/10 , C07K5/0606 , A61K38/00 , Y02P20/55
摘要： There are described compounds of formula ##STR1## in which n is 0, 1 or 2, R.sup.1 is a hydrocarbyl group optionally substituted with an optionally substituted phenyl group and containing from 5 to 30 carbon atoms, R.sup.2 is optionally substituted phenyl or C.sub.1-10 alkyl optionally substituted by one or more substituents selected from optionally protected hydroxyl, optionally protected carboxyl, nitrile, optionally protected tetrazolyl, --COR.sup.6 where R.sup.6 is C.sub.1-4 alkyl, C.sub.1-4 alkoxy, an optionally protected amino acid residue or --NR.sub.2.sup.7 where each R.sup.7 is hydrogen or C.sub.1-4 alkyl, and --NHR.sup.8 where R.sup.8 is hydrogen, a protecting group, an optionally protected amino acid residue, C.sub.1-4 alkyl or --COR.sup.9 where R.sup.9 is C.sub.1-4 alkyl or C.sub.1-4 alkoxy, and R.sup.3, R.sup.4 and R.sup.5 are each selected from hydrogen, carboxyl, C.sub.2-5 alkoxycarbonyl, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxyl, optionally protected tetrazolyl, halo, trifluoromethyl, nitrile, nitro and --CONR.sub.2.sup.10 where each R.sup.10 is hydrogen or C.sub.1-4 alkyl; and salts thereof. The compounds are leukotriene antagonists.
摘要翻译：描述了式（I）的化合物，其中n为0,1或2，R 1为任选被任选取代的苯基取代且含有5至30个碳原子的烃基，R 2为任选取代的苯基或任选受保护的羟基，任选保护的羧基，腈，任选受保护的四唑基，-COR 6，其中R 6为C 1-4烷基，C 1-4烷氧基，任选保护的氨基酸残基或-NR 27，其中每个 R7是氢或C1-4烷基，-NHR8，其中R8是氢，保护基，任选保护的氨基酸残基，C 1-4烷基或-COR 9，其中R 9是C 1-4烷基或C 1-4烷氧基，以及R 3，R 4和R 5 各自选自氢，羧基，C 2-5烷氧基羰基，C 1-4烷基，C 1-4烷氧基，羟基，任选保护的四唑基，卤素，三氟甲基，腈，硝基和-CONR210，其中每个R 10是氢或C 1-4烷基; 及其盐。这些化合物是白三烯拮抗剂。

4. 再颁专利

USRE32196E Aurone derivatives 失效
标题翻译： Aurone衍生物
公开(公告)号：USRE32196E
公开(公告)日：1986-07-01
申请号：US379793
申请日：1982-05-19
申请人： Stephen R. Baker , William B. Jamieson , William J. Ross
发明人： Stephen R. Baker , William B. Jamieson , William J. Ross
IPC分类号： C07D307/88 , A61K31/34 , A61K31/343 , A61P11/00 , C07C45/63 , C07C65/40 , C07D257/04 , C07D307/83 , C07D307/92 , C07D317/30 , C07D405/10
CPC分类号： C07D257/04 , C07C45/63 , C07C65/40 , C07D307/83 , C07D307/92 , C07D317/30
摘要： Substituted aurones of formula (I): ##STR1## wherein R.sup.1, R.sup.2 R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are the same or different and can each represent hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.3-8 cycloalkyl, optionally substituted phenyl, C.sub.1-6 haloalkyl, amido, amino, cyano, hydroxy, nitro, C.sub.2-4 alkenyl, carboxyl, tetrazol-5-yl and --CH.dbd.CHCOOH; orwherein R.sup.1 and R.sup.2 taken together can represent a group of formula --CH.dbd.CH--CH.dbd.CH-- provided that at least one of R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is carboxyl, tetrazol-5-yl or --CH.dbd.CHCOOH;or a pharmaceutically-acceptable salt or ester thereof, are effective in the prophylactic chemotherapy of allergic conditions such as bronchial asthma.
摘要翻译： AURONE DERIVAT IVES式（I）的取代的噢：其中R 1，R 2，R 3，R 4，R 5和R 6相同或不同并且各自表示氢，卤素，C 1-6烷基，C 1-6 烷氧基，C 3-8环烷基，任选取代的苯基，C 1-6卤代烷基，酰氨基，氨基，氰基，羟基，硝基，C 2-4烯基，羧基，四唑-5-基和-CH_CHCOOH; 或者其中R 1和R 2一起可以表示式-CH-CH-CH-CH-基团，条件是R 17，R 3，R 4，R 5和R 6中的至少一个是羧基，四唑-5-基或-CH = CICOOH; 或其药学上可接受的盐或酯在过敏性疾病例如支气管哮喘的预防性化学疗法中是有效的。

5. 发明授权

US4532257A Certain aurones and their use in the treatment of allergies 失效
标题翻译：某些ones ones及其用于治疗过敏症
公开(公告)号：US4532257A
公开(公告)日：1985-07-30
申请号：US556473
申请日：1983-11-30
申请人： Stephen R. Baker , Terry D. Lindstrom , William B. Jamieson , William J. Ross
发明人： Stephen R. Baker , Terry D. Lindstrom , William B. Jamieson , William J. Ross
IPC分类号： C07D307/83 , A61K31/34
CPC分类号： C07D307/83
摘要： There are described compounds of the formula ##STR1## in which either R.sup.1 and R.sup.2 are both hydrogen or R.sup.1 is carboxyl and R.sup.2 is hydrogen, C.sub.3-4 alkenyl or C.sub.1-4 alkyl, and R.sup.3, R.sup.4 and R.sup.5 are each hydrogen, nitro, hydroxyl, carboxyl, carboxyC.sub.1-2 alkoxy, C.sub.3-4 alkenyl, C.sub.1-4 alkyl, C.sub.3-4 alkenyloxy, C.sub.1-4 alkoxy or the group ##STR2## where R.sup.6 and R.sup.7 are each hydrogen or C.sub.1-4 alkyl; and salts and esters thereof. The compounds are indicated for use in the treatment of immediate sensitivity reactions and inflammatory diseases.
摘要翻译：描述了式“IMAGE”的化合物，其中R1和R2都是氢或R1是羧基，R2是氢，C3-4链烯基或C1-4烷基，R3，R4和R5各自是氢，硝基，羟基，羧基，羧基C 1-2烷氧基，C 3-4烯基，C 1-4烷基，C 3-4烯氧基，C 1-4烷氧基或基团，其中R 6和R 7各自为氢或C 1-4烷基; 及其盐和酯。该化合物用于治疗立即敏感反应和炎性疾病。

6. 发明授权

US4259340A Aurone derivatives 失效
标题翻译： Aurone衍生物
公开(公告)号：US4259340A
公开(公告)日：1981-03-31
申请号：US71515
申请日：1979-08-31
申请人： Stephen R. Baker , William B. Jamieson , William J. Ross
发明人： Stephen R. Baker , William B. Jamieson , William J. Ross
IPC分类号： C07C45/63 , C07C65/40 , C07D257/04 , C07D307/83 , C07D307/92 , C07D317/30 , C07D405/02 , C07D405/10
CPC分类号： C07D257/04 , C07C45/63 , C07C65/40 , C07D307/83 , C07D307/92 , C07D317/30 , Y10S514/826
摘要： Substituted aurones of formula (I): ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are the same or different and can each represent hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.3-8 cycloalkyl, optionally substituted phenyl, C.sub.1-6 haloalkyl, amido, amino, cyano, hydroxy, nitro, C.sub.2-4 alkenyl, carboxyl, tetrazol-5-yl and --CH.dbd.CHCOOH; orwherein R.sup.1 and R.sup.2 taken together can represent a group of formula --CH.dbd.CH--CH.dbd.CH-- provided that at least one of R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is carboxyl, tetrazol-5-yl or --CH.dbd.CHCOOH;or a pharmaceutically-acceptable salt or ester thereof, are effective in the prophylactic chemotherapy of allergic conditions such as bronchial asthma.
摘要翻译：取代的式（I）的噢：其中R 1，R 2，R 3，R 4，R 5和R 6相同或不同，各自表示氢，卤素，C 1-6烷基，C 1-6烷氧基，C 3 -8环烷基，任选取代的苯基，C 1-6卤代烷基，酰氨基，氨基，氰基，羟基，硝基，C 2-4烯基，羧基，四唑-5-基和-CH = CHCOOH; 或者其中R 1和R 2一起可以表示式-CH = CH-CH = CH-的基团，条件是R 1，R 2，R 3，R 4，R 5和R 6中的至少一个是羧基，四唑-5-基或-CH = CHCOOH; 或其药学上可接受的盐或酯在过敏性疾病例如支气管哮喘的预防性化学疗法中是有效的。

7. 发明授权

US4241073A Treatment of immediate hypersensitivity diseases with aryl hydantoins 失效
标题翻译：用芳基乙内酰脲治疗立即超敏反应疾病
公开(公告)号：US4241073A
公开(公告)日：1980-12-23
申请号：US39075
申请日：1979-05-14
申请人： William B. Jamieson , William J. Ross , Robin G. Simmonds , John P. Verge
发明人： William B. Jamieson , William J. Ross , Robin G. Simmonds , John P. Verge
IPC分类号： A61K31/415 , A61K31/4166 , A61P3/06 , A61P11/06 , A61P37/00 , C07D233/72 , C07D233/74 , C07D233/76 , C07D233/78 , C07D233/96 , C07D405/06 , C07D409/06
CPC分类号： C07D233/96 , C07D233/74 , C07D233/76 , C07D233/78 , Y10S514/826
摘要： Novel hydantoin compounds are described of the formula (I): ##STR1## wherein Ar is phenyl optionally substituted by up to three radicals selected from the group comprising C.sub.1-6 alkoxy, halogen, 1,3-dioxol-2-yl, hydroxy C.sub.1-4 alkoxy C.sub.1-4 alkyl, phenyl, hydroxyl, nitrile, C.sub.1-4 haloalkyl, C.sub.1-4 alkyl, C.sub.2-4 alkenyloxy, C.sub.1-4 alkoxycarbonyl or phenoxy optionally substituted by C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy or halogen;or is thiophene optionally substituted by phenyl or by one or two C.sub.1-4 alkyl groups;R.sup.1 and R.sup.2 are independently hydrogen or taken together represent a chemical bond;R.sup.3 is hydrogen, C.sub.1-6 alkyl or C.sub.2-4 alkenyl; andR.sup.4 is C.sub.1-6 alkyl, C.sub.2-4 alkenyl, phenyl or benzyl;provided that R.sup.3 cannot be hydrogen when Ar is unsubstituted phenyl and R.sup.4 is n-butyl. The compounds are useful in the treatment of immediate hypersensitivity diseases including asthma.
摘要翻译：描述了式（I）的新型乙内酰脲化合物：其中Ar是任选被至多三个选自下列的基团取代的苯基：C 1-6烷氧基，卤素，1,3-二氧杂环戊烯-2-基，羟基C 1-4烷氧基C 1-4烷基，苯基，羟基，腈，C 1-4卤代烷基，C 1-4烷基，C 2-4链烯氧基，C 1-4烷氧基羰基或任选被C 1-4卤代烷基取代的苯氧基，C 1-4烷氧基或卤素; 或任选被苯基或被一个或两个C 1-4烷基取代的噻吩; R1和R2独立地为氢或一起代表化学键; R3是氢，C1-6烷基或C2-4链烯基; R4为C1-6烷基，C2-4烯基，苯基或苄基; 条件是当Ar为未取代的苯基且R 4为正丁基时，R 3不能为氢。该化合物可用于治疗包括哮喘在内的立即超敏反应疾病。

8. 发明授权

US4293563A Thenyl hydantoins and anti-asthmatic compositions thereof 失效
标题翻译：噻菌灵乙内酯及其抗哮喘组合物
公开(公告)号：US4293563A
公开(公告)日：1981-10-06
申请号：US148633
申请日：1980-05-12
申请人： William B. Jamieson , William J. Ross , Robin G. Simmonds , John P. Verge
发明人： William B. Jamieson , William J. Ross , Robin G. Simmonds , John P. Verge
IPC分类号： A61K31/415 , A61K31/4166 , A61P3/06 , A61P11/06 , A61P37/00 , C07D233/72 , C07D233/74 , C07D233/76 , C07D233/78 , C07D233/96 , C07D405/06 , C07D409/06
CPC分类号： C07D233/96 , C07D233/74 , C07D233/76 , C07D233/78 , Y10S514/826
摘要： Novel hydantoin compounds are described of the formula (I): ##STR1## wherein Ar is phenyl optionally substituted by up to three radicals selected from the group comprising C.sub.1-6 alkoxy, halogen, 1,3-dioxol-2-yl, hydroxy C.sub.1-4 alkoxy C.sub.1-4 alkyl, phenyl, hydroxyl, nitrile, C.sub.1-4 haloalkyl, C.sub.1-4 alkyl, C.sub.2-4 alkenyloxy, C.sub.1-4 alkoxycarbonyl or phenoxy optionally substituted by C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy or halogen;or is thiophene optionally substituted by phenyl or by one or two C.sub.1-4 alkyl groups;R.sup.1 and R.sup.2 are independently hydrogen or taken together represent a chemical bond;R.sup.3 is hydrogen, C.sub.1-6 alkyl or C.sub.2-4 alkenyl; andR.sup.4 is C.sub.1-6 alkyl, C.sub.2-4 alkenyl, phenyl or benzyl;provided that R.sup.3 cannot be hydrogen when Ar is unsubstituted phenyl and R.sup.4 is n-butyl. The compounds are useful in the treatment of immediate hypersensitivity diseases including asthma.

9. 发明授权

US4230716A Treating immediate hypersensitivity conditions with 3,5-disubstituted hydantoin derivatives 失效
标题翻译：用3,5-二取代的乙内酰脲衍生物治疗立即超敏反应
公开(公告)号：US4230716A
公开(公告)日：1980-10-28
申请号：US39077
申请日：1979-05-14
申请人： William B. Jamieson , William J. Ross , Robin G. Simmonds , John P. Verge
发明人： William B. Jamieson , William J. Ross , Robin G. Simmonds , John P. Verge
IPC分类号： C07D233/74 , C07D233/76 , C07D233/78 , A61K31/415
CPC分类号： C07D233/76 , C07D233/74 , C07D233/78
摘要： Hydantoin compounds are described of the formula (I) : ##STR1## wherein R.sup.1 is phenyl, C.sub.1-4 hydroxyalkyl or carboxy C.sub.1-4 alkyl and wherein R.sub.2 is C.sub.1-6 alkyl. The compounds are useful in the prophylactic treatment of immediate hypersensitivity diseases including asthma.
摘要翻译：乙内酰脲化合物描述为式（I）：其中R 1是苯基，C 1-4羟基烷基或羧基C 1-4烷基，其中R 2是C 1-6烷基。该化合物可用于预防性治疗包括哮喘在内的立即超敏反应疾病。

10. 发明授权

US4230709A Method of treating asthma with alkyl, alkylidene and alkylene hydantoins 失效
标题翻译：用烷基，亚烷基和亚烷基乙内酰脲治疗哮喘的方法
公开(公告)号：US4230709A
公开(公告)日：1980-10-28
申请号：US39074
申请日：1979-05-14
申请人： William B. Jamieson , William J. Ross , Robin G. Simmonds , John P. Verge
发明人： William B. Jamieson , William J. Ross , Robin G. Simmonds , John P. Verge
IPC分类号： C07D233/74 , C07D233/96 , C07D235/02 , C07D487/04 , A61K31/445 , A61K31/415 , C07D233/58 , C07D471/04
CPC分类号： C07D235/02 , C07D233/74 , C07D233/96 , C07D487/04 , Y10S514/826
摘要： Pharmaceutical formulations are described, which comprise a hydantoin of formula (I): ##STR1## wherein R.sup.1 is C.sub.1-4 alkyl, R.sup.2 is hydrogen or C.sub.1-4 alkyl; or R.sup.1 and R.sup.2 taken together either represent a C.sub.4-6 alkylene group or a group of formula: ##STR2## where R.sup.5 and R.sup.6 independently represent hydrogen or C.sub.1-4 alkyl;R.sup.3 is C.sub.1-6 alkyl or benzyl;R.sup.4 is hydrogen or C.sub.1-6 alkyl;provided that R.sup.2 and R.sup.4 cannot both be hydrogen;or R.sup.1 and R.sup.4 taken together represent a C.sub.2-4 alkylene group;associated with a pharmaceutically-acceptable carrier therefor. The compounds, some of which are novel, are useful in the treatment of immediate hypersensitivity diseases such as asthma.
摘要翻译：描述了药物制剂，其包含式（I）的乙内酰脲：其中R 1是C 1-4烷基，R 2是氢或C 1-4烷基; 或者R 1和R 2一起表示C4-6亚烷基或下式的基团：其中R5和R6独立地表示氢或C1-4烷基; R3是C1-6烷基或苄基; R4是氢或C1-6烷基; 条件是R2和R4不能都是氢; 或者R 1和R 4一起代表C 2-4亚烷基; 与其药学上可接受的载体相关联。这些化合物，其中一些是新的，可用于治疗立即超敏反应性疾病如哮喘。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式